CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 254 filers reported holding CRISPR THERAPEUTICS AG in Q4 2019. The put-call ratio across all filers is 1.45 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $12,034,478 | -43.0% | 265,135 | -29.4% | 0.13% | -34.7% |
Q2 2023 | $21,096,738 | +906.4% | 375,788 | +710.8% | 0.20% | +818.2% |
Q1 2023 | $2,096,275 | -7.7% | 46,347 | -17.0% | 0.02% | -12.0% |
Q4 2022 | $2,271,156 | -89.1% | 55,871 | -82.5% | 0.02% | -89.8% |
Q3 2022 | $20,841,000 | +103.5% | 318,910 | +89.3% | 0.24% | +106.8% |
Q2 2022 | $10,239,000 | +10.3% | 168,485 | +13.9% | 0.12% | +40.5% |
Q1 2022 | $9,285,000 | +1802.7% | 147,917 | +4542.7% | 0.08% | +2000.0% |
Q4 2020 | $488,000 | +82.8% | 3,186 | -0.0% | 0.00% | +100.0% |
Q3 2020 | $267,000 | -97.7% | 3,187 | -98.0% | 0.00% | -98.1% |
Q2 2020 | $11,719,000 | +140.0% | 159,458 | +38.5% | 0.10% | +89.1% |
Q1 2020 | $4,882,000 | +4.6% | 115,112 | +50.2% | 0.06% | +61.8% |
Q4 2019 | $4,668,000 | +45.4% | 76,636 | +40.3% | 0.03% | +47.8% |
Q2 2018 | $3,210,000 | – | 54,631 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |